18:44 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting CASP1 could help treat AD. In primary human neurons overexpressing APP, a tool compound CASP1 inhibitor decreased axon degeneration compared with no treatment. In a...
18:11 , Aug 30, 2018 |  BC Innovations  |  Translation in Brief

Turning off the inflammasome

In a July Nature paper, a team from the University of California San Diego identified CMPK2 as a potential target for inflammatory diseases involving NLRP3 inflammasomes and may launch a spinout to develop the findings....
15:21 , Jul 19, 2018 |  BC Innovations  |  Translation in Brief

Inflammatory images

A University of Calgary team has implicated the inflammasome in acute kidney injury induced by contrast imaging agents and identified targets that could help prevent it. In patients with diminished renal function, such as those with...
17:48 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest inhibiting CASP1 could help treat MS. In patient postmortem brain tissue samples, levels of CASP1 were higher than in samples from unaffected subjects. In the experimental...
19:28 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

Castle Creek begins Phase II/III of topical diacerein to treat epidermolysis bullosa simplex

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) began the Phase II/III DELIVERS trial to evaluate topical 1% diacerein (AC-203, CCP-020) in about 80 patients ages ≥4 with epidermolysis bullosa simplex. The double-blind, international trial will test topical...
22:18 , Mar 24, 2017 |  BioCentury  |  Emerging Company Profile

Specificity in the inflammasome

Inflazome Ltd. is springboarding off an old Pfizer Inc. compound to design a collection of new inflammasome inhibitors targeted to specific cells and tissues to treat diseases including multiple sclerosis, Alzheimer’s disease and gout. The...
19:39 , Mar 2, 2017 |  BC Innovations  |  Emerging Company Profile

Unifying factor in NASH

While most companies pursuing NASH are tackling lipid metabolism, immune cell activation or bile acid transport, Jecure Therapeutics Inc. is aiming to treat the disease by blocking activation of the inflammasome, a cellular pathway it...
14:11 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Cell culture and mouse studies suggest inhibiting PKM2 could help treat sepsis. In lipopolysaccharide (LPS)-pretreated mouse bone marrow-derived macrophages and a human monocytic cell line, PKM2 knockdown or a PKM2 inhibitor tool compound decreased...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Caspase-1 (CASP1); α-synuclein (SNCA)

Neurology INDICATION: Parkinson's disease (PD) Patient sample and cell culture studies suggest inhibiting CASP1 could help treat PD. In postmortem brain tissue samples from PD patients, CASP1 was highly expressed in Lewy bodies. In a human dopaminergic...
07:00 , May 12, 2016 |  BC Innovations  |  Targets & Mechanisms

Another shot at the flu

While most efforts to suppress flu focus on boosting the immune system through vaccination, a group at Yale University has found evidence showing it is the inflammatory response to infection, not the infection itself, that...